EU MDR (2017/745)

EU MDR (2017/745) represents a change in how medical device manufacturers, distributors, and software developers approach compliance and safety in the European market. For DevSecOps leaders and security directors working with medical device software or SaMD (Software as a Medical Device), understanding this regulation has become non-negotiable. The Medical Device Regulation 2017/745 replaced the previous Medical Device Directive (MDD 93/42/EEC) to address gaps in oversight, strengthen post-market surveillance, and establish more rigorous requirements for clinical evidence and traceability throughout the entire software development lifecycle.

What is EU MDR (2017/745)?

The European Union Medical Device Regulation 2017/745, commonly known as EU MDR, is a comprehensive regulatory framework that governs the design, manufacture, distribution, and monitoring of medical devices sold within the European Economic Area. This regulation became applicable on May 26, 2021, after a transition period from its publication in 2017.

EU MDR establishes strict requirements for manufacturers to demonstrate that medical devices—including software that qualifies as a medical device—meet safety and performance standards before they can be placed on the market. The regulation covers everything from initial design and development through production, distribution, and post-market surveillance. For organizations developing medical device software, this means integrating compliance considerations into every stage of the SDLC (Software Development Lifecycle).

The regulation applies to a broad range of products, from traditional hardware medical devices like pacemakers and surgical instruments to increasingly prevalent software applications that diagnose, prevent, monitor, or treat medical conditions. Any organization that manufactures, distributes, or imports medical devices into the EU market must comply with EU MDR requirements, regardless of where the company is headquartered.

Definition of EU MDR Compliance Requirements

Compliance with EU MDR (2017/745) demands a multi-layered approach that touches every aspect of medical device development and distribution. The regulation introduces more stringent requirements compared to its predecessor directives, particularly in areas that directly impact DevSecOps practices.

Core Compliance Pillars

The regulatory framework rests on several foundational requirements that organizations must address:

• Technical Documentation: Comprehensive documentation proving conformity with safety and performance requirements, including detailed information about software architecture, cybersecurity measures, and risk management processes
• Clinical Evaluation: Rigorous clinical evidence demonstrating the device's safety and performance claims, with ongoing evaluation throughout the product lifecycle
• Quality Management System: ISO 13485-compliant QMS covering all stages of the device lifecycle from design through post-market activities
• Unique Device Identification: Implementation of UDI (Unique Device Identification) systems enabling traceability of devices throughout the supply chain
• Post-Market Surveillance: Continuous monitoring of device performance in real-world conditions with systematic collection and analysis of safety data
• Notified Body Assessment: For most device classes, independent third-party conformity assessment by an EU-recognized Notified Body

Software-Specific Requirements

For software development teams, EU MDR introduces specific considerations that align closely with modern DevSecOps practices. Software that qualifies as a medical device or is an accessory to a medical device must comply with requirements addressing software lifecycle processes, cybersecurity, and validation.

The regulation explicitly recognizes software as a medical device in its own right, particularly when it performs calculations, analysis, or provides information used to diagnose, prevent, monitor, predict, prognose, treat, or alleviate disease. This classification brings software development firmly within the regulatory scope, requiring developers to implement validated development processes, maintain comprehensive documentation, and establish robust cybersecurity measures.

Explanation of EU MDR Classification System

Understanding the EU MDR classification system is critical for determining the level of regulatory scrutiny your medical device software will face. The regulation categorizes medical devices into four classes based on risk: Class I (lowest risk), Class IIa, Class IIb, and Class III (highest risk).

Classification Rules for Medical Device Software

Medical device software classification under EU MDR (2017/745) follows specific rules outlined in Annex VIII. Rule 11 specifically addresses software classification based on the intended purpose and the potential harm if the software fails or provides incorrect information.

Software intended to provide information used to make decisions with diagnosis or therapeutic purposes is typically classified as:

• Class IIa: Software used for monitoring physiological processes or providing information about non-serious conditions
• Class IIb: Software used for monitoring vital physiological parameters where immediate danger could result from incorrect readings
• Class III: Software used for decisions that could result in death or irreversible deterioration of health

This classification directly impacts the conformity assessment route, clinical evidence requirements, and the depth of technical documentation needed. Higher classification means more rigorous third-party assessment and more extensive clinical evaluation.

How to Implement EU MDR Compliance in Your SDLC

Achieving and maintaining EU MDR compliance requires integrating regulatory requirements into your software development lifecycle from the earliest planning stages. For DevSecOps teams, this means treating compliance not as a final checkpoint but as a continuous thread woven throughout development, deployment, and maintenance.

Design and Development Phase Integration

During the design phase, teams must establish a comprehensive risk management process following ISO 14971. This involves identifying potential hazards associated with the software, estimating and evaluating risks, implementing risk control measures, and monitoring risk management effectiveness throughout the product lifecycle.

Documentation requirements begin at this stage as well. Teams need to maintain design specifications, architecture diagrams, interface specifications, and detailed records of design decisions. This documentation must demonstrate how the software addresses applicable general safety and performance requirements outlined in Annex I of EU MDR.

Software development must follow a defined, validated lifecycle process. Whether you use Agile, Waterfall, or hybrid methodologies, the chosen approach must be documented, justified, and followed consistently. Development activities should be traceable through version control systems, change management processes, and configuration management tools.

Cybersecurity and Supply Chain Security Considerations

EU MDR (2017/745) explicitly requires manufacturers to address cybersecurity risks throughout the device lifecycle. For medical device software, this means implementing security by design principles, conducting threat modeling, and establishing processes for identifying and addressing vulnerabilities.

Software supply chain security becomes particularly critical under EU MDR. The regulation requires manufacturers to maintain control over their supply chain, including third-party software components, open-source libraries, and development tools. Organizations must be able to demonstrate they understand the composition of their software, have evaluated the security of components, and can respond to vulnerabilities discovered in dependencies.

This is where modern Software Bill of Materials (SBOM) practices become valuable. Maintaining a comprehensive SBOM enables transparency into software components, facilitates vulnerability management, and supports the traceability requirements of EU MDR. The regulation's emphasis on traceability and post-market surveillance aligns well with supply chain security practices that track software components from development through deployment.

Verification and Validation Requirements

EU MDR requires comprehensive verification and validation of medical device software. Verification confirms that software outputs meet input requirements at each development stage, while validation ensures the finished software meets user needs and intended uses in real-world conditions.

Testing must be systematic, documented, and traceable to requirements. Test plans should address functional requirements, performance requirements, security requirements, and usability requirements. Testing environments should simulate intended use conditions, and test results must be documented and reviewed before release.

For DevSecOps teams, automated testing becomes both a compliance enabler and an efficiency driver. Automated unit tests, integration tests, security scans, and regression tests support continuous verification while generating the documentation trail required for regulatory compliance.

Release and Deployment Controls

Before releasing medical device software under EU MDR, organizations must complete a comprehensive conformity assessment. This assessment verifies that the software meets all applicable requirements and that appropriate documentation exists to demonstrate compliance.

Release processes should include defined approval gates, documented release criteria, and traceability between released versions and the underlying source code, test results, and risk management activities. Build processes should be reproducible, and organizations should maintain records demonstrating that released software matches validated builds.

Deployment must be controlled and monitored. Organizations need processes for tracking which software versions are deployed where, how updates are distributed, and how devices can be recalled or updated if safety issues emerge. This deployment visibility supports the post-market surveillance obligations under EU MDR.

Post-Market Surveillance and Vigilance Under EU MDR

EU MDR (2017/745) significantly strengthened post-market surveillance requirements compared to previous directives. Manufacturers must actively collect and analyze data about device performance in real-world use, identify safety signals, and take corrective action when necessary.

Post-Market Surveillance System Requirements

Every manufacturer must establish a post-market surveillance (PMS) system proportionate to the device class and appropriate for the device type. For software, this typically involves:

• Systematic collection of user feedback, complaints, and incident reports
• Active monitoring of scientific literature and similar devices on the market
• Analysis of software performance data and error logs
• Review of cybersecurity threat intelligence relevant to the device
• Regular evaluation of whether corrective or preventive action is needed

The PMS plan must be documented and updated regularly. Organizations should define data sources, collection methods, analysis approaches, and decision criteria for when intervention is required. This plan becomes part of the technical documentation reviewed during conformity assessment.

Incident Reporting and Field Safety Corrective Actions

When serious incidents occur or field safety corrective actions become necessary, EU MDR establishes strict timelines for reporting to competent authorities. A serious incident is any malfunction or deterioration that directly or indirectly led, might have led, or might lead to death or serious deterioration in health.

For software, this could include security breaches that expose patient data, calculation errors that lead to incorrect clinical decisions, or interface problems that cause user errors. Organizations must report serious incidents to the relevant national competent authority within specified timeframes—typically 15 days for death or serious deterioration, with initial notification sometimes required within 2 days for certain situations.

Field safety corrective actions (FSCAs) are actions taken by manufacturers to reduce risk or address non-compliance for devices already placed on the market. FSCAs might include software updates, usage restrictions, device recalls, or additional user warnings. These actions must be coordinated with notified bodies and competent authorities, with Field Safety Notices communicated to users.

Technical Documentation and EU MDR Compliance

The technical documentation required under EU MDR (2017/745) forms the foundation of the conformity assessment process. For medical device software, this documentation must demonstrate that the device meets all applicable requirements and that development followed appropriate processes.

Essential Technical Documentation Components

Annex II of EU MDR outlines the required technical documentation structure. Key sections relevant to software include:

• Device Description and Specifications: Detailed description of the software, its intended purpose, intended users, operating environment, and key features
• Design and Manufacturing Information: Description of the software development process, architecture, design specifications, and configuration management
• Risk Management: Complete risk management file showing hazard identification, risk analysis, risk evaluation, risk control measures, and residual risk assessment
• Verification and Validation: Test plans, test reports, traceability matrices, and validation studies demonstrating the software meets specifications and user needs
• Clinical Evaluation: Clinical evaluation report demonstrating clinical safety and performance through clinical data
• Post-Market Surveillance: PMS plan and periodic safety update reports summarizing data from real-world use

Maintaining Documentation Throughout the Product Lifecycle

Technical documentation isn't a one-time deliverable—it must be maintained and updated throughout the product lifecycle. When software is updated, documentation must reflect those changes. When new risks are identified through post-market surveillance, the risk management file must be updated. When clinical data accumulates, the clinical evaluation must be refreshed.

For organizations practicing continuous integration and continuous deployment, this creates interesting challenges. Regulatory documentation processes must keep pace with development velocity without becoming bottlenecks. Many organizations address this by automating documentation generation where possible, linking documentation to code through version control, and using tools that extract documentation from development artifacts.

EU MDR and Software as a Medical Device (SaMD)

Software as a Medical Device represents one of the fastest-growing categories under EU MDR. As healthcare increasingly relies on software for diagnosis, treatment decisions, and patient monitoring, regulatory scrutiny of these applications intensifies.

Defining SaMD Under EU MDR

EU MDR defines medical device software through its intended purpose. Software qualifies as a medical device when intended by the manufacturer for specific medical purposes like diagnosis, prevention, monitoring, prediction, prognosis, or treatment of disease. The software doesn't need to be embedded in hardware—standalone applications qualify if they meet the intended purpose criteria.

Common examples include diagnostic decision support software, treatment planning applications, medical image analysis tools, and patient monitoring applications. Even software that drives hardware devices or interprets device output may qualify as a medical device in its own right.

What's crucial for development teams is that general-purpose software used in healthcare settings doesn't automatically become a medical device. Software for administrative functions, general wellness, or lifestyle purposes typically falls outside the definition. The manufacturer's stated intended purpose and the specific claims made about the software determine regulatory status.

Special Considerations for AI and Machine Learning

Artificial intelligence and machine learning applications present unique challenges under EU MDR (2017/745). The regulation was written before AI became prevalent in medical applications, creating some uncertainty about how certain requirements apply to adaptive algorithms.

The fundamental challenge is that EU MDR assumes a medical device has fixed characteristics established during development and validated before market release. Machine learning models that adapt based on new data potentially change their characteristics after deployment, which creates questions about when and how validation occurs.

Current guidance suggests that significant algorithm changes requiring new training data or substantially altering performance characteristics should be treated as modifications requiring conformity reassessment. Organizations developing AI-based medical devices need robust processes for monitoring algorithm performance, detecting drift, controlling updates, and maintaining documentation of algorithm versions deployed.

Notified Body Involvement and Conformity Assessment

Most medical device software requires involvement of a Notified Body—an independent organization designated by EU member states to assess conformity with EU MDR. Understanding when Notified Body involvement is required and what that process entails helps organizations plan compliance timelines and resources.

When Notified Body Assessment is Required

Class I medical devices generally don't require Notified Body involvement for most aspects of conformity assessment, though sterile or measuring Class I devices do. Class IIa, IIb, and III devices all require Notified Body assessment before they can be placed on the EU market.

Most medical device software falls into Class IIa or higher classifications, meaning Notified Body involvement is required. The specific conformity assessment route depends on the classification, with higher-risk devices requiring more extensive third-party review.

Notified Bodies assess the technical documentation, audit the quality management system, and verify that products meet EU MDR requirements. For software, this includes reviewing development processes, verification and validation evidence, cybersecurity measures, and risk management activities.

Choosing and Working with a Notified Body

Not all Notified Bodies are equal. Organizations should select a Notified Body with experience in software and medical device software specifically. The Notified Body should understand modern software development practices, cybersecurity principles, and the specific technical challenges of your device type.

Working effectively with a Notified Body requires preparation. Before initiating the conformity assessment, ensure your technical documentation is complete, your quality management system is implemented and functional, and your development processes are mature. Notified Bodies assess what's in place, not what you plan to implement.

Communication is key. Establish clear points of contact, understand the Notified Body's expectations and review processes, and respond promptly to questions or requests for additional information. The conformity assessment timeline depends heavily on how efficiently you can provide information the Notified Body needs.

Quality Management System Requirements

EU MDR requires manufacturers to establish, document, implement, and maintain a quality management system ensuring consistent compliance with the regulation. For most organizations, this means implementing a QMS aligned with ISO 13485, the international standard for medical device quality management.

Key QMS Elements for Software Organizations

A compliant QMS must address the complete product lifecycle from design through post-market activities. Critical elements for software organizations include:

• Management Responsibility: Clear assignment of responsibilities, management review of QMS effectiveness, and allocation of adequate resources
• Resource Management: Competent personnel, appropriate infrastructure, and controlled work environment
• Product Realization: Controlled processes for design, development, production, and service delivery
• Measurement and Analysis: Monitoring of processes and products, handling of nonconformities, and continuous improvement

For software development, the QMS should integrate with existing development processes rather than creating parallel bureaucracy. Modern DevSecOps practices often align well with QMS requirements—version control provides configuration management, automated testing supports verification, and continuous integration enables controlled builds.

Integrating QMS with DevSecOps Practices

Organizations practicing DevSecOps can leverage existing tools and processes to meet QMS requirements efficiently. Version control systems provide traceability and configuration management. Issue tracking systems document change requests and problem reports. Continuous integration pipelines enforce controlled build processes. Automated testing generates verification evidence.

The key is documenting how these tools and processes fulfill QMS requirements. Create procedures that describe your development workflow, explain how the workflow meets regulatory requirements, and demonstrate that you actually follow the documented processes. Audit trails from development tools can provide objective evidence of compliance.

Transitioning from MDD to EU MDR

Organizations that achieved compliance under the previous Medical Device Directive faced a challenging transition to EU MDR (2017/745). While the MDD certificates have expired, understanding the transition helps contextualize the differences between the regulatory frameworks.

Key Differences Between MDD and EU MDR

EU MDR introduced substantially more rigorous requirements compared to MDD across multiple areas:

• More detailed technical documentation requirements with explicit sections for cybersecurity and software lifecycle
• Stricter clinical evidence requirements with higher standards for clinical evaluation reports
• Enhanced post-market surveillance obligations with mandatory periodic safety update reports
• Unique device identification and traceability systems not required under MDD
• More rigorous Notified Body assessment processes with unannounced audits
• Expanded economic operator obligations covering distributors and importers
• Increased transparency through EUDAMED database registration

For software specifically, EU MDR brought greater regulatory clarity about standalone software classification while imposing more detailed requirements for software development, validation, and cybersecurity.

Cybersecurity Requirements Under EU MDR

While EU MDR (2017/745) doesn't include a dedicated cybersecurity chapter, it explicitly requires manufacturers to address cybersecurity throughout the device lifecycle. Annex I includes specific requirements for protection against cybersecurity threats, making security a fundamental safety requirement rather than an optional consideration.

Security by Design Principles

EU MDR requires devices to be designed and manufactured to protect against cybersecurity threats. For medical device software, this means implementing security throughout the development lifecycle, not adding it as an afterthought.

Security by design involves threat modeling during design, selecting secure architectures and components, implementing defense-in-depth strategies, and validating security controls. Development teams should identify potential attack vectors, assess the impact of successful attacks, and implement appropriate countermeasures.

Common security controls for medical device software include authentication and authorization mechanisms, encryption of data at rest and in transit, secure communication protocols, input validation, secure software update mechanisms, and audit logging. The specific controls depend on the device's intended use environment and the sensitivity of data processed.

Vulnerability Management and Coordinated Disclosure

Post-market cybersecurity requirements under EU MDR include monitoring for vulnerabilities, assessing their impact, and taking corrective action when necessary. Manufacturers must stay informed about cybersecurity threats relevant to their devices and respond appropriately when vulnerabilities are discovered.

This includes vulnerabilities in third-party components. When a vulnerability is disclosed in an open-source library or commercial component used in your medical device software, you need processes to assess whether your device is affected, evaluate the risk, and decide whether a software update or other corrective action is needed.

Organizations should establish coordinated vulnerability disclosure processes allowing security researchers to report vulnerabilities responsibly. Many medical device manufacturers publish vulnerability disclosure policies explaining how to report security issues and what timeline reporters can expect for assessment and remediation.

Supply Chain Traceability and Software Transparency

EU MDR's emphasis on traceability extends to software components and development supply chains. Manufacturers must maintain control over their supply chains and be able to trace components, understand their provenance, and respond to safety issues affecting third-party elements.

Software Bill of Materials Best Practices

Maintaining a comprehensive Software Bill of Materials has become a best practice for medical device software under EU MDR. An SBOM provides an inventory of software components, including open-source libraries, commercial components, and internally developed modules.

A well-maintained SBOM enables rapid response when vulnerabilities are disclosed in components. Rather than manually searching code to determine if a vulnerable library is present, teams can query the SBOM to identify affected products immediately. This supports both cybersecurity risk management and post-market surveillance obligations.

SBOMs also facilitate conformity assessment by demonstrating transparency about software composition. Notified Bodies may request information about third-party components, their validation, and how they're controlled. An SBOM provides a foundation for answering these questions.

Managing Open Source Components

Open source software presents both opportunities and challenges under EU MDR. Open source components can accelerate development and provide well-tested functionality, but manufacturers remain fully responsible for ensuring these components meet regulatory requirements.

Organizations using open source in medical device software should establish processes for evaluating components before use, tracking versions deployed, monitoring for vulnerabilities and updates, and validating that components function correctly in their specific context. License compliance also matters—some open source licenses may be incompatible with medical device commercialization.

Documentation should explain why specific open source components were selected, what alternatives were considered, how the components were validated, and how they're maintained. This demonstrates the considered approach to software development that regulators expect.

Leveraging Modern Tools for EU MDR Compliance

Meeting EU MDR (2017/745) requirements for medical device software doesn't mean abandoning modern development practices. The right tools and platforms can support both regulatory compliance and development efficiency.

Supply chain security platforms help organizations maintain visibility into software composition, track component versions, identify vulnerabilities, and generate SBOMs automatically. These capabilities directly support EU MDR requirements for traceability, cybersecurity risk management, and post-market surveillance.

For organizations developing medical device software and looking to streamline compliance while maintaining security, exploring purpose-built solutions can provide significant value. Schedule a demo to see how Kusari's supply chain security platform can help your team maintain the software transparency and traceability required under EU MDR while integrating seamlessly with your existing DevSecOps workflows.

What are the main requirements of EU MDR (2017/745)?

The main requirements of EU MDR (2017/745) encompass comprehensive obligations across the entire medical device lifecycle. EU MDR requires manufacturers to establish and maintain a quality management system covering design, development, production, and post-market activities. Technical documentation must demonstrate that devices meet safety and performance requirements outlined in Annex I, with particular attention to risk management, clinical evaluation, and verification and validation activities.

For medical device software specifically, EU MDR requires validated development processes following defined software lifecycle procedures, comprehensive cybersecurity risk assessment and mitigation, and detailed documentation of software architecture, verification testing, and validation studies. Post-market surveillance systems must actively collect and analyze real-world performance data, with serious incidents reported to competent authorities within strict timeframes. Most devices require conformity assessment by a Notified Body before they can be placed on the EU market, with the depth of assessment depending on device classification.

The regulation also mandates implementation of unique device identification systems enabling traceability throughout the supply chain, periodic safety update reports summarizing post-market surveillance findings, and transparency through registration in the EUDAMED database. These EU MDR requirements create a robust framework ensuring medical devices meet consistent safety and performance standards across the European market.

How does EU MDR (2017/745) affect software development teams?

EU MDR (2017/745) significantly affects software development teams creating medical device software by imposing regulatory requirements throughout the software development lifecycle. Development teams must follow defined, validated software development processes with documentation demonstrating that established procedures are actually followed. This affects everything from requirements management and architecture decisions to coding standards, testing approaches, and release procedures.

The regulation requires comprehensive verification and validation activities, meaning development teams need systematic testing strategies with documented test plans, test cases, and test results traceable to requirements. EU MDR's cybersecurity requirements mean security can't be an afterthought—teams must integrate security from initial design through deployment and maintenance, conducting threat modeling, implementing appropriate security controls, and monitoring for vulnerabilities.

Configuration management becomes more rigorous under EU MDR, with requirements for version control, change management, and traceability between released software versions and underlying source code and test results. Development teams need visibility into software composition, including third-party components and open-source libraries, to support vulnerability management and post-market surveillance. These EU MDR requirements push development teams toward mature DevSecOps practices with automated testing, continuous integration, comprehensive documentation, and robust supply chain security measures.

What is the difference between EU MDR and previous medical device regulations?

The difference between EU MDR (2017/745) and previous medical device regulations, particularly the Medical Device Directive (MDD 93/42/EEC), lies in significantly more stringent requirements across nearly every aspect of medical device oversight. EU MDR introduced more comprehensive technical documentation requirements with detailed sections addressing software development, cybersecurity, and supply chain management that were less explicit under MDD.

Clinical evidence requirements became substantially more rigorous under EU MDR, with higher standards for clinical evaluation reports and greater emphasis on ongoing clinical follow-up. The previous regulations allowed more flexibility in demonstrating equivalence to existing devices, while EU MDR tightened requirements for equivalence claims and increased expectations for device-specific clinical data.

Post-market surveillance transformed from a relatively light-touch requirement under MDD to a comprehensive system under EU MDR, with mandatory periodic safety update reports, stricter vigilance obligations, and explicit requirements for post-market clinical follow-up. EU MDR introduced unique device identification and traceability systems not required under previous regulations, enhancing transparency and enabling better monitoring of devices throughout their lifecycle. Notified Body oversight became more intensive under EU MDR with unannounced audits and stricter designation criteria for Notified Bodies themselves. These differences between EU MDR and previous regulations reflect lessons learned from safety incidents and gaps in the earlier regulatory framework.

How long does EU MDR (2017/745) conformity assessment take?

The EU MDR (2017/745) conformity assessment timeline varies significantly based on device classification, the completeness of technical documentation, the organization's quality management system maturity, and Notified Body capacity. For Class IIa medical device software with well-prepared documentation and an established quality management system, the conformity assessment process typically takes between 6 to 12 months from initial application to certificate issuance.

Class IIb and Class III devices generally require longer timelines, often 12 to 18 months or more, due to more extensive technical review and quality management system auditing requirements under EU MDR. These timelines assume the organization has already developed the device, implemented its quality management system, and prepared technical documentation before engaging the Notified Body. The actual development and preparation phase often takes considerably longer than the Notified Body assessment itself.

Several factors can extend EU MDR conformity assessment timelines substantially. Incomplete or poor-quality technical documentation triggers multiple review cycles as the Notified Body requests additional information or clarification. Quality management system nonconformities identified during audits require corrective action and follow-up verification. Limited Notified Body capacity, particularly for software and complex devices, can create scheduling delays for audits and reviews. Organizations new to medical device regulation often underestimate the time required to establish compliant processes and documentation, leading to longer overall timelines before they're ready for Notified Body assessment under EU MDR (2017/745).

Navigating EU MDR Compliance Successfully

Achieving and maintaining compliance with EU MDR (2017/745) represents a significant undertaking for organizations developing medical device software, but the regulation's requirements align well with modern DevSecOps best practices when approached strategically. The emphasis on validated development processes, comprehensive testing, cybersecurity risk management, and supply chain transparency reflects principles that mature software organizations already embrace.

Success with EU MDR compliance comes from treating regulatory requirements as integrated aspects of your development process rather than separate compliance activities bolted onto existing workflows. Organizations that embed risk management, verification, validation, and documentation into their standard development practices find compliance more sustainable and less disruptive than those maintaining separate regulatory and development tracks.

The investment in EU MDR compliance infrastructure—quality management systems, technical documentation processes, post-market surveillance capabilities—pays dividends beyond European market access. Many other regulatory frameworks, including FDA requirements in the United States and regulatory schemes in other markets, share similar principles around risk management, validation, and post-market monitoring. Building mature processes for EU MDR (2017/745) creates a foundation supporting global market access and, more importantly, genuinely improves product quality and patient safety.